PDF(Pubmed)
Abstract：
To investigate biometric and refractive results in patients with type 1 retinopathy of prematurity (ROP) treated by intravitreal injection (IVI) of ranibizumab (R) and bevacizumab (B) at the corrected age of 6. This is a single-center retrospective study. Infants diagnosed with type 1 ROP and treated with IVI of either R or B as the primary therapy were included. Data on axial length, anterior chamber depth (ACD), and lens thickness (LT) were obtained using A-scan ultrasound. Cycloplegic refraction, keratometry (K), and best-corrected visual acuity were also documented. Additionally, optical coherence tomography angiography was performed to assess the foveal avascular zone and the density of superficial and deep vessels. We analyzed the structural and functional differences between the 2 groups and compared them with findings from a previous study conducted when these children were between the ages of 1 and 3. The study included 60 eyes from 34 patients, with 34 eyes receiving B and 26 eyes receiving R injections for ROP. In biometric outcomes, there was still a deeper ACD (3.36 ± 0.24 mm in the B group; 3.52 ± 0.21 mm in the R group) and thinner LT (3.63 ± 0.16 mm in the B group; 3.53 ± 0.12 mm in the R group) in the R group, as previously reported at the age of 3. In the refractive aspect, the eyes treated with B had higher myopia at the ages of 1 and 3; however, at the age of 6, refractive errors did not differ significantly between the 2 groups. At the corrected age of 6, the eyes treated with IVI of R were associated with deeper ACD and thinner LT. Interestingly, the emmetropization process resulted in a similar incidence of high myopia at the age of 6, which was different from the outcomes observed at younger ages.
摘要：
探讨1型早产儿视网膜病变(ROP)患者在校正年龄6岁时玻璃体腔注射(IVI)雷珠单抗(R)和贝伐单抗(B)的生物识别和屈光检查结果。这是一项单中心回顾性研究。包括诊断为1型ROP并以R或B的IVI作为主要疗法的婴儿。轴向长度数据，前房深度（ACD），和晶状体厚度（LT）使用A扫描超声获得。晶状体麻痹屈光,角膜曲率测量（K），并记录了最佳矫正视力。此外,进行光学相干断层扫描血管造影以评估中央凹无血管区以及浅血管和深血管的密度。我们分析了两组之间的结构和功能差异，并将其与先前研究中这些儿童在1至3岁之间的研究结果进行了比较。该研究包括34名患者的60只眼睛，34只眼接受B，26只眼接受R注射进行ROP。在生物识别结果中，R组仍有较深的ACD(B组3.36±0.24mm;R组3.52±0.21mm)和较薄的LT(B组3.63±0.16mm;R组3.53±0.12mm),正如以前在3岁时报道的那样。在折射方面，用B治疗的眼睛在1岁和3岁时近视较高；然而，6岁时,两组间屈光不正无显著差异.在校正的6岁时，用R的IVI治疗的眼睛与更深的ACD和更薄的LT相关。有趣的是,正视化过程导致6岁时高度近视的发生率相似,这与年轻时观察到的结果不同.
